|
ATCC
human osteosarcoma cells u2os ![]() Human Osteosarcoma Cells U2os, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pmc13127698-142-20-24?v=ATCC Average 99 stars, based on 1 article reviews
human osteosarcoma cells u2os - by Bioz Stars,
2026-07
99/100 stars
|
Buy from Supplier |
|
Procell Inc
human osteosarcoma cell lines u2os ![]() Human Osteosarcoma Cell Lines U2os, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pmc13273694-40-0-12?v=Procell+Inc Average 86 stars, based on 1 article reviews
human osteosarcoma cell lines u2os - by Bioz Stars,
2026-07
86/100 stars
|
Buy from Supplier |
|
Servicebio Inc
human osteosarcoma cell lines u2os ![]() Human Osteosarcoma Cell Lines U2os, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pm42280476-57-1-21?v=Servicebio+Inc Average 86 stars, based on 1 article reviews
human osteosarcoma cell lines u2os - by Bioz Stars,
2026-07
86/100 stars
|
Buy from Supplier |
|
ATCC
human osteosarcoma cell line u2os ![]() Human Osteosarcoma Cell Line U2os, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pm41963733-240-13-18?v=ATCC Average 99 stars, based on 1 article reviews
human osteosarcoma cell line u2os - by Bioz Stars,
2026-07
99/100 stars
|
Buy from Supplier |
|
ATCC
human osteosarcoma cell lines u2os ![]() Human Osteosarcoma Cell Lines U2os, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/bio_rxiv__64898__2026__03__30__715387-217-0-11?v=ATCC Average 98 stars, based on 1 article reviews
human osteosarcoma cell lines u2os - by Bioz Stars,
2026-07
98/100 stars
|
Buy from Supplier |
|
ATCC
collection human u2os osteosarcoma cells ![]() Collection Human U2os Osteosarcoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pm41914023-37-4-10?v=ATCC Average 99 stars, based on 1 article reviews
collection human u2os osteosarcoma cells - by Bioz Stars,
2026-07
99/100 stars
|
Buy from Supplier |
|
ATCC
u2os human osteosarcoma cells ![]() U2os Human Osteosarcoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pmc12962177-297-0-4?v=ATCC Average 99 stars, based on 1 article reviews
u2os human osteosarcoma cells - by Bioz Stars,
2026-07
99/100 stars
|
Buy from Supplier |
|
ATCC
research cell line source s human osteosarcoma u2os cells ![]() Research Cell Line Source S Human Osteosarcoma U2os Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/u2os+human+osteosarcoma+cells/pm41857122-523-13-38?v=ATCC Average 99 stars, based on 1 article reviews
research cell line source s human osteosarcoma u2os cells - by Bioz Stars,
2026-07
99/100 stars
|
Buy from Supplier |
Journal: Chembiochem
Article Title: Monoclonal Antibodies Accessing the Cytosol of Living Cells and Binding to Polo‐Like Kinase 1 Interdomain Linker Affect Mitotic Behavior
doi: 10.1002/cbic.202500858
Figure Lengend Snippet: Anti‐PLK1 mAbs characterization. (A) Clones 35‐206, 3F8, and 13E8 were raised against full‐length PLK1, fragment 300–600, or fragment 300–400, respectively. KD: Kinase Domain; IDL: Interdomain Linker; PBD: Polo Box Domain. (B) Epitope mapping by Western blot. Lane 1: protein ladder; Lanes 2‐4: U2OS cells expressing 68 kDa PLK1, 14 kDa IDL (300–400), or 35 kDa IDL‐PBD (300–603), respectively.
Article Snippet: Human cervical carcinoma cells HeLa (ATCC Cat# CCL‐2, RRID:CVCL_0030), histone‐green fluorescent protein expressing HeLa cells H2BGFP‐HeLa (SCC117, Merck Millipore, RRID:CVCL_ZM02),
Techniques: Clone Assay, Western Blot, Expressing
Journal: bioRxiv
Article Title: Cytoplasmic capping enzyme targeted, hypoxia-responsive RNAs, RORA and KCTD16 modulate the aggressiveness of CoCl 2 -induced hypoxic osteosarcoma cells
doi: 10.64898/2026.03.30.715387
Figure Lengend Snippet: ( A and C ) Representative microscopic images of BrdU incorporation assays in U2OS and MG63 osteosarcoma cells under normoxic (control) and CoCl 2 induced hypoxic conditions. Scale bar = 50 μm. ( B and D ) Quantification of BrdU-positive cells showing a significant decrease in proliferation in hypoxic U2OS and MG63 cells compared with their respective controls (n ≥ 20 cells per condition). ( E and G ) Representative images of colony-formation assays in control and CoCl₂-treated hypoxic U2OS and MG63 cells, respectively. (F and H) Quantification of colony numbers showing a marked reduction in the clonogenic potential of hypoxic osteosarcoma cells. ( I and K ). Representative images of cell-migration assays in U2OS and MG63 cells under control and hypoxic conditions. Scale bar = 50 µm. ( J and L) Quantification of migrated cells showed a significant reduction in the migratory capacity of hypoxic U2OS and MG63 cells, respectively. Statistical significance was calculated using two-tailed Student’s t -test and is represented as mean ± SD from three biological replicates. ns: non-significant, *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001.
Article Snippet:
Techniques: BrdU Incorporation Assay, Control, Migration, Two Tailed Test
Journal: bioRxiv
Article Title: Cytoplasmic capping enzyme targeted, hypoxia-responsive RNAs, RORA and KCTD16 modulate the aggressiveness of CoCl 2 -induced hypoxic osteosarcoma cells
doi: 10.64898/2026.03.30.715387
Figure Lengend Snippet: ( A ) U2OS cells, either stably expressing K294A upon doxycycline induction or uninduced controls, were biochemically fractionated into nuclear and cytoplasmic compartments. Western blot analysis confirmed fractionation quality using Lamin A/C as a nuclear marker and GAPDH as a cytoplasmic marker. Myc blotting verified the expression of K294A upon doxycycline induction. ( B ) Quantitative real-time PCR analysis revealed a significant reduction in the cytoplasmic levels of RORA and KCTD16 transcripts in K294A expressing cells compared with controls, while BNIP3 levels remained unchanged. ( C ) Western blot analysis further confirmed decreased protein levels of RORA and KCTD16 in K294A-expressing cells. Myc blotting verified stable K294A expression. ( D ) Densitometric analysis of RORA and KCTD16 protein bands from panel C was performed using ImageJ software. β-Actin was used as a loading control for normalization. Statistical analysis was calculated by performing two-tailed Student’s t -test. ( E ) Table summarizing the internal CAGE (Cap Analysis of Gene Expression) sites identified within the analysed transcripts, with the specific positions highlighted in red. ( F - J ) Bar graphs representing the genomic distribution of CAGE peaks for each gene, illustrating the relative frequency of CAGE signals across different transcript regions. ( K ) Schematic illustration of the Xrn1 susceptibility assay used to assess the stability of 5′-capped transcripts. ( L ) Relative 5′-end loss of RORA and KCTD16 was assessed using an in vitro Xrn1 susceptibility assay. In K294A-expressing cells, both transcripts exhibited a level of 5′-end loss comparable to STAT3 , a known cCE target, relative to control cells. Statistical analysis was performed using one sample Student’s t -test. ( M ) Western blot analysis showing Xrn1 protein levels in Xrn1 knockdown cells with or without doxycycline-induced K294A expression. Myc detection confirmed successful induction of the dominant-negative cCE mutant. ( N ) Quantification of Xrn1 knockdown efficiency was performed using ImageJ software, with β-Actin serving as the internal loading control. ( O ) RORA and KCTD16 exhibited the most pronounced rescue in Xrn1 knockdown cells expressing K294A, indicating their strong dependence on cytoplasmic capping for stability. Statistical significance was determined using one-way ANOVA. All the data is represented as mean ± SD from three biological replicates. ns: non-significant, *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001.
Article Snippet:
Techniques: Stable Transfection, Expressing, Western Blot, Fractionation, Marker, Real-time Polymerase Chain Reaction, Software, Control, Two Tailed Test, Gene Expression, Drug Susceptibility Assay, In Vitro, Knockdown, Dominant Negative Mutation, Mutagenesis
Journal: bioRxiv
Article Title: Cytoplasmic capping enzyme targeted, hypoxia-responsive RNAs, RORA and KCTD16 modulate the aggressiveness of CoCl 2 -induced hypoxic osteosarcoma cells
doi: 10.64898/2026.03.30.715387
Figure Lengend Snippet: ( A and B ) qPCR analysis of the selected transcripts in U2OS and MG63 cells revealed reduced expression following treatment with the HIF1α inhibitor PX478, irrespective of hypoxia induction. ( C and E ) Western blot analysis of U2OS and MG63 cells demonstrated reduced protein levels of all selected targets, including HIF1α, in PX478-treated hypoxic samples. ( D and F ) Quantification of western blot band intensities corresponding to panels C and E was performed using ImageJ software. β-Actin served as the loading control for normalization. Data are presented as mean ± SD from three biological replicates. Statistical significance was determined using one-way ANOVA. ns, not significant; *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001.
Article Snippet:
Techniques: Expressing, Western Blot, Software, Control
Journal: bioRxiv
Article Title: Cytoplasmic capping enzyme targeted, hypoxia-responsive RNAs, RORA and KCTD16 modulate the aggressiveness of CoCl 2 -induced hypoxic osteosarcoma cells
doi: 10.64898/2026.03.30.715387
Figure Lengend Snippet: ( A ) Western blot analysis of c-Myc protein levels in U2OS cells under normoxic and CoCl₂-induced hypoxic conditions. ( B ) Densitometric quantification of c-Myc expression from panel A using ImageJ, showing reduced c-Myc levels in hypoxic U2OS cells. β-Actin served as the loading control. Statistical significance was determined using two-tailed Student’s t -test. ( C and E ) Western blots showing siRNA-mediated depletion of RORA ( C ) and KCTD16 ( I ) in U2OS and MG63 cells under hypoxic conditions. HIF1α blot confirms hypoxia induction. c-Myc levels were elevated upon depletion of either gene. ( D and J ) ImageJ-based densitometric quantification of blots from panels C and I , normalized to β-actin. Statistical analysis was performed using one-way ANOVA. ( E and K ) Representative microscopic images of BrdU incorporation assays in RORA and KCTD16 depleted hypoxic U2OS and MG63 cells, respectively. Scale bar = 50 μm. ( F and L ) Quantification of BrdU-positive cells showing increased proliferation upon RORA or KCTD16 depletion under hypoxic conditions (n ≥ 20 cells per condition). ( G and M ) Representative images of colony formation assays in RORA-and KCTD16-depleted hypoxic osteosarcoma cells. ( H and N ) Quantitative analysis showing enhanced clonogenic potential following RORA or KCTD16 depletion in hypoxic cells. Statistical significance was calculated using one-way ANOVA. All the data is represented as ± SD from three biological replicates. ns: non-significant, *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001.
Article Snippet:
Techniques: Western Blot, Expressing, Control, Two Tailed Test, BrdU Incorporation Assay
Journal: bioRxiv
Article Title: Cytoplasmic capping enzyme targeted, hypoxia-responsive RNAs, RORA and KCTD16 modulate the aggressiveness of CoCl 2 -induced hypoxic osteosarcoma cells
doi: 10.64898/2026.03.30.715387
Figure Lengend Snippet: ( A and I ) Western blots showing RORA, KCTD16, and c-Myc levels in U2OS and MG63 cells, respectively. ( B and J ) Densitometric quantification of the blots using ImageJ demonstrated that overexpression of RORA or KCTD16 led to reduced c-Myc expression in both cell lines. β-Actin was used as a loading control for normalization. ( C and K ) Representative microscopic images of BrdU incorporation assays in RORA and KCTD16 overexpressing U2OS and MG63 cells, respectively. Scale bar = 50 μm. ( D and L ) Quantification of BrdU-positive cells showing significantly decreased proliferative capacity in RORA and KCTD16-overexpressing cells (n ≥ 20 cells per condition). ( E and M ) Representative images of colony formation assays in RORA and KCTD16 overexpressing osteosarcoma cells. ( F and N ) Quantification of colonies demonstrating a marked reduction in clonogenic potential upon RORA or KCTD16 overexpression. ( G and O ) Representative images of migration assays in RORA and KCTD16-overexpressing cells. Scale bar = 50 μm. ( H and P ) Quantification of migrated cells showing significantly impaired migratory capacity in RORA and KCTD16 overexpressing osteosarcoma cells. Statistical analysis was performed using one-way ANOVA, and all data are presented as mean ± SD from three independent biological replicates. Significance is indicated as follows: ns, not significant; *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.0001.
Article Snippet:
Techniques: Western Blot, Over Expression, Expressing, Control, BrdU Incorporation Assay, Migration
Journal: iScience
Article Title: Predicting DNA damage response using synthetic cell painting profiles and experimental analysis
doi: 10.1016/j.isci.2026.115000
Figure Lengend Snippet: Application of the model to external datasets and experimental testing (A) Principal component analysis plot for the idr-0080 and cpg-0012 datasets. (B) Classification of cpg-0012 compounds into high-DDR (9,923) and low-DDR (20,694) groups. The high-DDR group includes known DNA damage inducers. Test compounds without prior DDR annotation were selected from the high-DDR (tetrindole, KF38789, and LY2183240) and low-DDR (amoxapine, acetazolamide, and captopril) groups. Flow cytometric (C) and Western blot (D) analyses of γH2AX expression in U2OS cells following 18 h treatment with 10 μM test compounds. (E) U2OS cells were treated with high-DDR candidates at increasing doses or with 10 μM low-DDR candidates for 72 h, and cell viability was measured using the CellTiter-Glo assay. Data are shown as means ± SD from independent experiments. One-way ANOVA with LSD post hoc test was used for statistical analysis. ∗ , p < 0.05; ∗∗∗ , p < 0.001 versus vehicle.
Article Snippet:
Techniques: Western Blot, Expressing, Glo Assay
Journal: iScience
Article Title: Predicting DNA damage response using synthetic cell painting profiles and experimental analysis
doi: 10.1016/j.isci.2026.115000
Figure Lengend Snippet:
Article Snippet:
Techniques: Recombinant, Flow Cytometry, Software